echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Hengrui received clinical approval for many new drugs

    Hengrui received clinical approval for many new drugs

    • Last Update: 2021-12-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On November 26, Hengrui issued an announcement that two clinical trial applications were approved by the National Food and Drug Administration: Carrelizumab combined with famitinib malate and paclitaxel for injection (albumin-bound) for the treatment of patients with advanced solid tumors An open, multi-center phase Ib/II clinical study; SHR-1701 injection combined with lenvatinib mesylate capsules vs.


    Carrelizumab is a humanized anti-PD-1 monoclonal antibody that can bind to human PD-1 receptors and block the PD-1/PD-L1 pathway, restore the body’s anti-tumor immunity, and form cancer The basis of immunotherapy


    Famitinib malate capsules are small molecule multi-target tyrosine kinase inhibitors


    SHR-1701 can promote the activation of effector T cells, and at the same time can effectively improve the immune regulation in the tumor microenvironment, and ultimately effectively promote the immune system to kill tumor cells


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.